| Product Information | |
|---|---|
| Catalog#: | MK1203H |
| Product Name: | Recombinant Human CD47 Protein, Fc Chimera |
| Description: | Leukocyte surface antigen CD47 is also known as Antigenic surface determinant protein OA3, Integrin-associated protein (IAP) and Protein MER6. CD47 contains 1 Ig-like V-type (immunoglobulin-like) domain. CD47 is a 40‑60 kDa variably glycosylated atypical member of the immunoglobulin superfamily and an integral membrane protein that consists of a 123 amino acid (aa) extracellular domain (ECD) with a single Ig-like domain, five membrane-spanning regions with short intervening loops, and a 34 aa C-terminal cytoplasmic tail. CD47 has a role in both cell adhesion by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins and plays an important role in memory formation and synaptic plasticity in the hippocampus by similarity. CD47 is the receptor for SIRPA, binding to which prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. CD47 Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and costimulates T-cell activation. |
| Source: | HEK293 cells |
| Species: | Human |
| Tag: | Fc |
| Protein length: | Gln19-Pro139 |
| Purity: | > 97% as determined by SDS-PAGE. |
| Storage: | Store under sterile conditions at -20 °C to -80 °C. Avoid repeated freeze-thaw cycles. |
| Reconstitution: | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH2O or PBS up to 100 μg/mL. |
| Molecular Mass: | 60-65 kDa, on SDS-PAGE under reducing conditions. |
| Stability: | Upon receiving, the product remains stable for 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. |
| Endotoxin: | < 0.2 EU/μg of protein by gel clotting method. |
| Notes: | Research Use Only. Not for use in clinical procedures. |
Enter your email here to subscribe